



## Clinical trial results:

### BI 655066/ABBV-066 (risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Incomplete Adalimumab Treatment Response (IMMvent)

#### Summary

|                          |                   |
|--------------------------|-------------------|
| EudraCT number           | 2015-003623-65    |
| Trial protocol           | DE SE FI PT CZ PL |
| Global end of trial date | 24 August 2017    |

#### Results information

|                                |                   |
|--------------------------------|-------------------|
| Result version number          | v1 (current)      |
| This version publication date  | 09 September 2018 |
| First version publication date | 09 September 2018 |

#### Trial information

##### Trial identification

|                       |         |
|-----------------------|---------|
| Sponsor protocol code | 1311.30 |
|-----------------------|---------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT02694523 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                                                                                               |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Boehringer Ingelheim                                                                                                                                          |
| Sponsor organisation address | Binger Strasse 173, Ingelheim am Rhein, Germany, 55216                                                                                                        |
| Public contact               | QRPE Processes and Systems Coordination Clinical Trial Information Disclosure, Boehringer Ingelheim, 001 8002430127, clintrriage.rdg@boehringer-ingelheim.com |
| Scientific contact           | QRPE Processes and Systems Coordination Clinical Trial Information Disclosure, Boehringer Ingelheim, 001 8002430127, clintrriage.rdg@boehringer-ingelheim.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

---

|                                                      |                  |
|------------------------------------------------------|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 05 October 2017  |
| Is this the analysis of the primary completion data? | Yes              |
| Primary completion date                              | 01 February 2017 |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 24 August 2017   |
| Was the trial ended prematurely?                     | No               |

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The main objectives of this study were to assess the efficacy and safety of risankizumab compared with adalimumab in subjects with moderate to severe chronic plaque psoriasis, and the efficacy and safety of switching to risankizumab compared with continued adalimumab in patients with an inadequate response to adalimumab at Week 16.

Protection of trial subjects:

Only patients that met all the study inclusion and none of the exclusion criteria were to be entered in the study. All patients were free to withdraw from the clinical trial at any time for any reason given. Close monitoring of all patients was adhered to throughout the trial conduct. Rescue medication was allowed for all patients as required.

Background therapy: -

Evidence for comparator: -

|                                                           |               |
|-----------------------------------------------------------|---------------|
| Actual start date of recruitment                          | 31 March 2016 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | Yes           |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Canada: 94         |
| Country: Number of subjects enrolled | Czech Republic: 29 |
| Country: Number of subjects enrolled | Finland: 10        |
| Country: Number of subjects enrolled | France: 21         |
| Country: Number of subjects enrolled | Germany: 88        |
| Country: Number of subjects enrolled | Mexico: 21         |
| Country: Number of subjects enrolled | Poland: 79         |
| Country: Number of subjects enrolled | Portugal: 22       |
| Country: Number of subjects enrolled | Sweden: 12         |
| Country: Number of subjects enrolled | Taiwan: 58         |
| Country: Number of subjects enrolled | United States: 250 |
| Worldwide total number of subjects   | 684                |
| EEA total number of subjects         | 261                |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|-------------------------------------------|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 621 |
| From 65 to 84 years                       | 63  |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

Confirmatory,Randomized,DoubleBlind,DoubleDummy,ActiveControlled,ParallelDesign trial to compare risankizumab with adalimumab in patients with moderate to severe chronic plaque psoriasis. Randomization ratio was 1:1 to risankizumab or adalimumab, stratified by weight and by prior exposure to TNF antagonists. 684 were enrolled and 605 were treated.

### Pre-assignment

Screening details:

Patients were randomized to adalimumab or risankizumab inPartA. Who received risankizumab continued risankizumab in PartB;adalimumab responders( $\geq$ PsoriasisArea andSeverityIndex(PASI)90) continued adalimumab,nonresponders( $<$ PASI50) switched to risankizumab,indadequate responders(PASI50to $<$ PASI90)were rerandomized to adalimumab or risankizumab inPartB.

### Period 1

|                              |                         |
|------------------------------|-------------------------|
| Period 1 title               | Part A                  |
| Is this the baseline period? | Yes                     |
| Allocation method            | Randomised - controlled |
| Blinding used                | Double blind            |
| Roles blinded                | Subject, Investigator   |

Blinding implementation details:

This was a double-blind trial. Patients were randomized in blocks to double-blind treatments.

### Arms

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |                     |
|------------------|---------------------|
| <b>Arm title</b> | Adalimumab (Part A) |
|------------------|---------------------|

Arm description:

Participants randomized to receive double-blind adalimumab 80 milligram (mg) at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).

|                                        |                   |
|----------------------------------------|-------------------|
| Arm type                               | Active comparator |
| Investigational medicinal product name | Adalimumab        |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Injection         |
| Routes of administration               | Subcutaneous use  |

Dosage and administration details:

Participants randomized to receive double-blind adalimumab 80 mg at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).

|                  |                       |
|------------------|-----------------------|
| <b>Arm title</b> | Risankizumab (Part A) |
|------------------|-----------------------|

Arm description:

Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A) continued to receive risankizumab at Weeks 16 and 28.

|                                        |                  |
|----------------------------------------|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | Risankizumab     |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A) continued to receive risankizumab at Weeks 16 and 28.

| <b>Number of subjects in period 1<sup>[1]</sup></b> | Adalimumab (Part A) | Risankizumab (Part A) |
|-----------------------------------------------------|---------------------|-----------------------|
| Started                                             | 304                 | 301                   |
| Completed                                           | 291                 | 294                   |
| Not completed                                       | 13                  | 7                     |
| Consent withdrawn by subject                        | 3                   | 1                     |
| Adverse event, non-fatal                            | 7                   | 3                     |
| Not Specified                                       | 1                   | 1                     |
| Lost to follow-up                                   | 1                   | 2                     |
| Protocol deviation                                  | 1                   | -                     |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Baseline characteristics are based on patients who were randomised after successfully completing the screening period and received at least one dose of the trial medication.

## Period 2

|                              |                         |
|------------------------------|-------------------------|
| Period 2 title               | Part B                  |
| Is this the baseline period? | No                      |
| Allocation method            | Randomised - controlled |
| Blinding used                | Double blind            |
| Roles blinded                | Subject, Investigator   |

Blinding implementation details:

This was a double-blind trial. Patients were randomized in blocks to double-blind treatments.

## Arms

|                              |                                    |
|------------------------------|------------------------------------|
| Are arms mutually exclusive? | Yes                                |
| <b>Arm title</b>             | Risankizumab/Risankizumab (Part B) |

Arm description:

Participants randomized to receive double-blind risankizumab in Part A continued to receive risankizumab 150 mg at Weeks 16, and 28 (Part B).

|                                        |                  |
|----------------------------------------|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | Risankizumab     |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants randomized to receive double-blind risankizumab in Part A continued to receive risankizumab 150 mg at Weeks 16, and 28 (Part B).

|                  |                                |
|------------------|--------------------------------|
| <b>Arm title</b> | Adalimumab/Adalimumab (Part B) |
|------------------|--------------------------------|

Arm description:

Participants who were responders after receiving adalimumab in Part A continued adalimumab 40 mg every other week through Week 41 (Part B).

|          |                   |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

|                                        |                  |
|----------------------------------------|------------------|
| Investigational medicinal product name | Adalimumab       |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants who were responders after receiving adalimumab in Part A continued adalimumab 40 mg every other week through Week 41 (Part B).

|                  |                                  |
|------------------|----------------------------------|
| <b>Arm title</b> | Adalimumab/Risankizumab (Part B) |
|------------------|----------------------------------|

Arm description:

Participants who were nonresponders after receiving adalimumab in Part A switched to risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).

|                                        |                  |
|----------------------------------------|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | Risankizumab     |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants who were nonresponders after receiving adalimumab in Part A switched to risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).

|                  |                                                |
|------------------|------------------------------------------------|
| <b>Arm title</b> | Adalimumab/Rerandomized to Adalimumab (Part B) |
|------------------|------------------------------------------------|

Arm description:

Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to continue to receive adalimumab 40 mg every 2 weeks through Week 41 (Part B).

|                                        |                   |
|----------------------------------------|-------------------|
| Arm type                               | Active comparator |
| Investigational medicinal product name | Adalimumab        |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Injection         |
| Routes of administration               | Subcutaneous use  |

Dosage and administration details:

Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to continue to receive adalimumab 40 mg every 2 weeks through Week 41 (Part B).

|                  |                                                  |
|------------------|--------------------------------------------------|
| <b>Arm title</b> | Adalimumab/Rerandomized to Risankizumab (Part B) |
|------------------|--------------------------------------------------|

Arm description:

Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to receive risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).

|                                        |                  |
|----------------------------------------|------------------|
| Arm type                               | Experimental     |
| Investigational medicinal product name | Risankizumab     |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to receive risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).

| <b>Number of subjects in period 2</b> | <b>Risankizumab/Risankizumab (Part B)</b> | <b>Adalimumab/Adalimumab (Part B)</b> | <b>Adalimumab/Risankizumab (Part B)</b> |
|---------------------------------------|-------------------------------------------|---------------------------------------|-----------------------------------------|
| Started                               | 294                                       | 144                                   | 38                                      |
| Completed                             | 274                                       | 140                                   | 34                                      |
| Not completed                         | 20                                        | 4                                     | 4                                       |
| Consent withdrawn by subject          | 9                                         | -                                     | 1                                       |
| Adverse event, non-fatal              | 7                                         | 1                                     | 1                                       |
| Not Specified                         | 1                                         | -                                     | -                                       |
| Lost to follow-up                     | 2                                         | 3                                     | 2                                       |
| Protocol deviation                    | 1                                         | -                                     | -                                       |

| <b>Number of subjects in period 2</b> | <b>Adalimumab/Rerandomized to Adalimumab (Part B)</b> | <b>Adalimumab/Rerandomized to Risankizumab (Part B)</b> |
|---------------------------------------|-------------------------------------------------------|---------------------------------------------------------|
| Started                               | 56                                                    | 53                                                      |
| Completed                             | 51                                                    | 51                                                      |
| Not completed                         | 5                                                     | 2                                                       |
| Consent withdrawn by subject          | 3                                                     | -                                                       |
| Adverse event, non-fatal              | 2                                                     | -                                                       |
| Not Specified                         | -                                                     | 1                                                       |
| Lost to follow-up                     | -                                                     | 1                                                       |
| Protocol deviation                    | -                                                     | -                                                       |

## Baseline characteristics

### Reporting groups

|                                                                                                                                                       |                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Reporting group title                                                                                                                                 | Adalimumab (Part A)   |
| Reporting group description:                                                                                                                          |                       |
| Participants randomized to receive double-blind adalimumab 80 milligram (mg) at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A). |                       |
| Reporting group title                                                                                                                                 | Risankizumab (Part A) |
| Reporting group description:                                                                                                                          |                       |
| Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A) continued to receive risankizumab at Weeks 16 and 28.                       |                       |

| Reporting group values | Adalimumab (Part A) | Risankizumab (Part A) | Total |
|------------------------|---------------------|-----------------------|-------|
| Number of subjects     | 304                 | 301                   | 605   |
| Age categorical        |                     |                       |       |
| Units: Subjects        |                     |                       |       |

|                                                                                                                                                   |         |         |     |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------|-----|
| Age Continuous                                                                                                                                    |         |         |     |
| Age at the time of signing informed consent form is presented. Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline. |         |         |     |
| Units: years                                                                                                                                      |         |         |     |
| arithmetic mean                                                                                                                                   | 47.0    | 45.3    |     |
| standard deviation                                                                                                                                | ± 13.09 | ± 13.79 | -   |
| Sex: Female, Male                                                                                                                                 |         |         |     |
| Number of subjects is categorized as Male or Female. Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.           |         |         |     |
| Units: Subjects                                                                                                                                   |         |         |     |
| Female                                                                                                                                            | 92      | 91      | 183 |
| Male                                                                                                                                              | 212     | 210     | 422 |
| Race (NIH/OMB)                                                                                                                                    |         |         |     |
| Number of subjects is categorized for race data. Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.               |         |         |     |
| Units: Subjects                                                                                                                                   |         |         |     |
| American Indian or Alaska Native                                                                                                                  | 0       | 2       | 2   |
| Asian                                                                                                                                             | 35      | 41      | 76  |
| Native Hawaiian or Other Pacific Islander                                                                                                         | 0       | 0       | 0   |
| Black or African American                                                                                                                         | 6       | 11      | 17  |
| White                                                                                                                                             | 263     | 245     | 508 |
| More than one race                                                                                                                                | 0       | 2       | 2   |
| Unknown or Not Reported                                                                                                                           | 0       | 0       | 0   |
| Ethnicity (NIH/OMB)                                                                                                                               |         |         |     |
| Number of subjects is categorized for ethnicity data. Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline.          |         |         |     |
| Units: Subjects                                                                                                                                   |         |         |     |
| Hispanic or Latino                                                                                                                                | 59      | 44      | 103 |
| Not Hispanic or Latino                                                                                                                            | 245     | 257     | 502 |



## End points

### End points reporting groups

|                                                                                                                                                                                                                     |                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Reporting group title                                                                                                                                                                                               | Adalimumab (Part A)                              |
| Reporting group description:<br>Participants randomized to receive double-blind adalimumab 80 milligram (mg) at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).                               |                                                  |
| Reporting group title                                                                                                                                                                                               | Risankizumab (Part A)                            |
| Reporting group description:<br>Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A) continued to receive risankizumab at Weeks 16 and 28.                                                     |                                                  |
| Reporting group title                                                                                                                                                                                               | Risankizumab/Risankizumab (Part B)               |
| Reporting group description:<br>Participants randomized to receive double-blind risankizumab in Part A continued to receive risankizumab 150 mg at Weeks 16, and 28 (Part B).                                       |                                                  |
| Reporting group title                                                                                                                                                                                               | Adalimumab/Adalimumab (Part B)                   |
| Reporting group description:<br>Participants who were responders after receiving adalimumab in Part A continued adalimumab 40 mg every other week through Week 41 (Part B).                                         |                                                  |
| Reporting group title                                                                                                                                                                                               | Adalimumab/Risankizumab (Part B)                 |
| Reporting group description:<br>Participants who were nonresponders after receiving adalimumab in Part A switched to risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).                                          |                                                  |
| Reporting group title                                                                                                                                                                                               | Adalimumab/Rerandomized to Adalimumab (Part B)   |
| Reporting group description:<br>Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to continue to receive adalimumab 40 mg every 2 weeks through Week 41 (Part B). |                                                  |
| Reporting group title                                                                                                                                                                                               | Adalimumab/Rerandomized to Risankizumab (Part B) |
| Reporting group description:<br>Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to receive risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).                |                                                  |

### Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) |
| End point description:<br>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. Nonresponder imputation (NRI) was used for missing data. Intent-to-treat population in Part A (ITT_A): All subjects randomized at Baseline. |                                                                                                                                     |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Primary                                                                                                                             |
| End point timeframe:<br>Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                     |

| End point values                  | Adalimumab (Part A) | Risankizumab (Part A) |  |  |
|-----------------------------------|---------------------|-----------------------|--|--|
| Subject group type                | Reporting group     | Reporting group       |  |  |
| Number of subjects analysed       | 304 <sup>[1]</sup>  | 301 <sup>[2]</sup>    |  |  |
| Units: Percentage of participants |                     |                       |  |  |
| number (not applicable)           | 47.4                | 72.4                  |  |  |

Notes:

[1] - ITT\_A population

[2] - ITT\_A population

## Statistical analyses

| Statistical analysis title                                                                                                                                                                                              | Statistical Analysis 1                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Statistical analysis description:                                                                                                                                                                                       |                                             |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kilogram (kg) vs $> 100$ kg) and prior exposure to Tumor Necrosis Factor (TNF) antagonists (0 vs $\geq 1$ ). |                                             |
| Comparison groups                                                                                                                                                                                                       | Adalimumab (Part A) v Risankizumab (Part A) |
| Number of subjects included in analysis                                                                                                                                                                                 | 605                                         |
| Analysis specification                                                                                                                                                                                                  | Pre-specified                               |
| Analysis type                                                                                                                                                                                                           | other                                       |
| P-value                                                                                                                                                                                                                 | $< 0.001$                                   |
| Method                                                                                                                                                                                                                  | Cochran-Mantel-Haenszel                     |
| Parameter estimate                                                                                                                                                                                                      | Difference in percentage of participants    |
| Point estimate                                                                                                                                                                                                          | 24.9                                        |
| Confidence interval                                                                                                                                                                                                     |                                             |
| level                                                                                                                                                                                                                   | 95 %                                        |
| sides                                                                                                                                                                                                                   | 2-sided                                     |
| lower limit                                                                                                                                                                                                             | 17.5                                        |
| upper limit                                                                                                                                                                                                             | 32.4                                        |

## Primary: Percentage of Participants Achieving Static Physician Global Assessment (sPGA) score of Clear or Almost Clear at Week 16 (Part A)

|                 |                                                                                                                                   |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Achieving Static Physician Global Assessment (sPGA) score of Clear or Almost Clear at Week 16 (Part A) |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|

End point description:

The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean  $> 0$ ,  $< 1.5$ ; Mild (2) = mean  $\geq 1.5$ ,  $< 2.5$ ; Moderate (3) = mean  $\geq 2.5$ ,  $< 3.5$ ; and Severe (4) = mean  $\geq 3.5$ . No Response Imputation (NRI) was used for missing data.

|                      |         |
|----------------------|---------|
| End point type       | Primary |
| End point timeframe: |         |
| Week 16              |         |

| End point values                  | Adalimumab (Part A) | Risankizumab (Part A) |  |  |
|-----------------------------------|---------------------|-----------------------|--|--|
| Subject group type                | Reporting group     | Reporting group       |  |  |
| Number of subjects analysed       | 304 <sup>[3]</sup>  | 301 <sup>[4]</sup>    |  |  |
| Units: Percentage of participants |                     |                       |  |  |
| number (not applicable)           | 60.2                | 83.7                  |  |  |

Notes:

[3] - ITT\_A population

[4] - ITT\_A population

## Statistical analyses

| Statistical analysis title                                                                                                                                                           | Statistical Analysis 2                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                             |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                             |
| Comparison groups                                                                                                                                                                    | Adalimumab (Part A) v Risankizumab (Part A) |
| Number of subjects included in analysis                                                                                                                                              | 605                                         |
| Analysis specification                                                                                                                                                               | Pre-specified                               |
| Analysis type                                                                                                                                                                        | other                                       |
| P-value                                                                                                                                                                              | $< 0.001$                                   |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                     |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants    |
| Point estimate                                                                                                                                                                       | 23.3                                        |
| Confidence interval                                                                                                                                                                  |                                             |
| level                                                                                                                                                                                | 95 %                                        |
| sides                                                                                                                                                                                | 2-sided                                     |
| lower limit                                                                                                                                                                          | 16.6                                        |
| upper limit                                                                                                                                                                          | 30.1                                        |

## Primary: Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)

|                 |                                                                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B) |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data. Intent-to-treat population in Part B who were re-randomized (ITT\_B\_RR): All subjects who started with adalimumab at Baseline and were re-randomized at Week 16.

|                      |         |
|----------------------|---------|
| End point type       | Primary |
| End point timeframe: |         |
| Week 44              |         |

| End point values                  | Adalimumab/Rerandomized to Adalimumab (Part B) | Adalimumab/Rerandomized to Risankizumab (Part B) |  |  |
|-----------------------------------|------------------------------------------------|--------------------------------------------------|--|--|
| Subject group type                | Reporting group                                | Reporting group                                  |  |  |
| Number of subjects analysed       | 56 <sup>[5]</sup>                              | 53 <sup>[6]</sup>                                |  |  |
| Units: Percentage of participants |                                                |                                                  |  |  |
| number (not applicable)           | 21.4                                           | 66.0                                             |  |  |

Notes:

[5] - ITT\_B\_RR population

[6] - ITT\_B\_RR population

## Statistical analyses

| Statistical analysis title                                                                                                                                                           | Statistical Analysis 3                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                                                                                   |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                                                                                   |
| Comparison groups                                                                                                                                                                    | Adalimumab/Rerandomized to Adalimumab (Part B) v Adalimumab/Rerandomized to Risankizumab (Part B) |
| Number of subjects included in analysis                                                                                                                                              | 109                                                                                               |
| Analysis specification                                                                                                                                                               | Pre-specified                                                                                     |
| Analysis type                                                                                                                                                                        | other                                                                                             |
| P-value                                                                                                                                                                              | $< 0.001$                                                                                         |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                                                                           |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants                                                          |
| Point estimate                                                                                                                                                                       | 45                                                                                                |
| Confidence interval                                                                                                                                                                  |                                                                                                   |
| level                                                                                                                                                                                | 95 %                                                                                              |
| sides                                                                                                                                                                                | 2-sided                                                                                           |
| lower limit                                                                                                                                                                          | 28.9                                                                                              |
| upper limit                                                                                                                                                                          | 61.1                                                                                              |

## Secondary: Percentage of Participants Achieving PASI75 at Week 16 (Part A)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Percentage of Participants Achieving PASI75 at Week 16 (Part A) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                 |
| <p>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</p> |                                                                 |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Secondary                                                       |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                 |
| Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                 |

| End point values                  | Adalimumab (Part A) | Risankizumab (Part A) |  |  |
|-----------------------------------|---------------------|-----------------------|--|--|
| Subject group type                | Reporting group     | Reporting group       |  |  |
| Number of subjects analysed       | 304 <sup>[7]</sup>  | 301 <sup>[8]</sup>    |  |  |
| Units: Percentage of participants |                     |                       |  |  |
| number (not applicable)           | 71.7                | 90.7                  |  |  |

Notes:

[7] - ITT\_A population

[8] - ITT\_A population

## Statistical analyses

| Statistical analysis title                                                                                                                                                           | Statistical Analysis 4                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                             |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                             |
| Comparison groups                                                                                                                                                                    | Adalimumab (Part A) v Risankizumab (Part A) |
| Number of subjects included in analysis                                                                                                                                              | 605                                         |
| Analysis specification                                                                                                                                                               | Pre-specified                               |
| Analysis type                                                                                                                                                                        | other                                       |
| P-value                                                                                                                                                                              | $< 0.001$                                   |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                     |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants    |
| Point estimate                                                                                                                                                                       | 18.9                                        |
| Confidence interval                                                                                                                                                                  |                                             |
| level                                                                                                                                                                                | 95 %                                        |
| sides                                                                                                                                                                                | 2-sided                                     |
| lower limit                                                                                                                                                                          | 13                                          |
| upper limit                                                                                                                                                                          | 24.9                                        |

## Secondary: Percentage of Participants Achieving PASI100 at Week 16 (Part A)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Percentage of Participants Achieving PASI100 at Week 16 (Part A) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                  |
| <p>PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline * 100. NRI was used for missing data.</p> |                                                                  |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Secondary                                                        |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                  |
| Week 16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                  |

| End point values                  | Adalimumab (Part A) | Risankizumab (Part A) |  |  |
|-----------------------------------|---------------------|-----------------------|--|--|
| Subject group type                | Reporting group     | Reporting group       |  |  |
| Number of subjects analysed       | 304 <sup>[9]</sup>  | 301 <sup>[10]</sup>   |  |  |
| Units: Percentage of participants |                     |                       |  |  |
| number (not applicable)           | 23.0                | 39.9                  |  |  |

Notes:

[9] - ITT\_A population

[10] - ITT\_A population

## Statistical analyses

| Statistical analysis title                                                                                                                                                           | Statistical Analysis 5                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                             |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                             |
| Comparison groups                                                                                                                                                                    | Adalimumab (Part A) v Risankizumab (Part A) |
| Number of subjects included in analysis                                                                                                                                              | 605                                         |
| Analysis specification                                                                                                                                                               | Pre-specified                               |
| Analysis type                                                                                                                                                                        | other                                       |
| P-value                                                                                                                                                                              | $< 0.001$                                   |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                     |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants    |
| Point estimate                                                                                                                                                                       | 16.7                                        |
| Confidence interval                                                                                                                                                                  |                                             |
| level                                                                                                                                                                                | 95 %                                        |
| sides                                                                                                                                                                                | 2-sided                                     |
| lower limit                                                                                                                                                                          | 9.5                                         |
| upper limit                                                                                                                                                                          | 23.9                                        |

## Secondary: Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)

|                 |                                                                                                                                                |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B) |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI100 is defined as a 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. NRI was used for missing data.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 44              |           |

| End point values                  | Adalimumab/Rerandomized to Adalimumab (Part B) | Adalimumab/Rerandomized to Risankizumab (Part B) |  |  |
|-----------------------------------|------------------------------------------------|--------------------------------------------------|--|--|
| Subject group type                | Reporting group                                | Reporting group                                  |  |  |
| Number of subjects analysed       | 56 <sup>[11]</sup>                             | 53 <sup>[12]</sup>                               |  |  |
| Units: Percentage of participants |                                                |                                                  |  |  |
| number (not applicable)           | 7.1                                            | 39.6                                             |  |  |

Notes:

[11] - ITT\_B\_RR population

[12] - ITT\_B\_RR population

## Statistical analyses

| Statistical analysis title                                                                                                                                                           | Statistical Analysis 6                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                                                                                   |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                                                                                   |
| Comparison groups                                                                                                                                                                    | Adalimumab/Rerandomized to Adalimumab (Part B) v Adalimumab/Rerandomized to Risankizumab (Part B) |
| Number of subjects included in analysis                                                                                                                                              | 109                                                                                               |
| Analysis specification                                                                                                                                                               | Pre-specified                                                                                     |
| Analysis type                                                                                                                                                                        | other                                                                                             |
| P-value                                                                                                                                                                              | $< 0.001$                                                                                         |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                                                                           |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants                                                          |
| Point estimate                                                                                                                                                                       | 32.8                                                                                              |
| Confidence interval                                                                                                                                                                  |                                                                                                   |
| level                                                                                                                                                                                | 95 %                                                                                              |
| sides                                                                                                                                                                                | 2-sided                                                                                           |
| lower limit                                                                                                                                                                          | 18.8                                                                                              |
| upper limit                                                                                                                                                                          | 46.9                                                                                              |

## Secondary: Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA score of Clear at Week 44 (Part B)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA score of Clear at Week 44 (Part B) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean $>0$ , $<1.5$ ; Mild (2) = mean $\geq 1.5$ , $<2.5$ ; Moderate (3) = mean $\geq 2.5$ , $<3.5$ ; and Severe (4) = mean $\geq 3.5$ . NRI was used for missing data. |                                                                                                                                                            |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Secondary                                                                                                                                                  |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                            |
| Week 44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                            |

| End point values                  | Adalimumab/Rerandomized to Adalimumab (Part B) | Adalimumab/Rerandomized to Risankizumab (Part B) |  |  |
|-----------------------------------|------------------------------------------------|--------------------------------------------------|--|--|
| Subject group type                | Reporting group                                | Reporting group                                  |  |  |
| Number of subjects analysed       | 56 <sup>[13]</sup>                             | 53 <sup>[14]</sup>                               |  |  |
| Units: Percentage of participants |                                                |                                                  |  |  |
| number (not applicable)           | 7.1                                            | 39.6                                             |  |  |

Notes:

[13] - ITT\_B\_RR population

[14] - ITT\_B\_RR population

## Statistical analyses

| Statistical analysis title                                                                                                                                                           | Statistical Analysis 7                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                                                                                   |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                                                                                   |
| Comparison groups                                                                                                                                                                    | Adalimumab/Rerandomized to Adalimumab (Part B) v Adalimumab/Rerandomized to Risankizumab (Part B) |
| Number of subjects included in analysis                                                                                                                                              | 109                                                                                               |
| Analysis specification                                                                                                                                                               | Pre-specified                                                                                     |
| Analysis type                                                                                                                                                                        | other                                                                                             |
| P-value                                                                                                                                                                              | $< 0.001$                                                                                         |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                                                                           |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants                                                          |
| Point estimate                                                                                                                                                                       | 32.8                                                                                              |
| Confidence interval                                                                                                                                                                  |                                                                                                   |
| level                                                                                                                                                                                | 95 %                                                                                              |
| sides                                                                                                                                                                                | 2-sided                                                                                           |
| lower limit                                                                                                                                                                          | 18.8                                                                                              |
| upper limit                                                                                                                                                                          | 46.9                                                                                              |

## Other pre-specified: Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA score of Clear or Almost Clear at Week 44 (Part B)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA score of Clear or Almost Clear at Week 44 (Part B) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                            |
| The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean $>0$ , $<1.5$ ; Mild (2) = mean $\geq 1.5$ , $<2.5$ ; Moderate (3) = mean $\geq 2.5$ , $<3.5$ ; and Severe (4) = mean $\geq 3.5$ . NRI was used for missing data. |                                                                                                                                                                            |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Other pre-specified                                                                                                                                                        |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                            |
| Week 44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                            |



| <b>End point values</b>           | Adalimumab/Rerandomized to Adalimumab (Part B) | Adalimumab/Rerandomized to Risankizumab (Part B) |  |  |
|-----------------------------------|------------------------------------------------|--------------------------------------------------|--|--|
| Subject group type                | Reporting group                                | Reporting group                                  |  |  |
| Number of subjects analysed       | 56 <sup>[15]</sup>                             | 53 <sup>[16]</sup>                               |  |  |
| Units: Percentage of participants |                                                |                                                  |  |  |
| number (not applicable)           | 33.9                                           | 73.6                                             |  |  |

Notes:

[15] - ITT\_B\_RR population

[16] - ITT\_B\_RR population

## Statistical analyses

| <b>Statistical analysis title</b>                                                                                                                                                    | Statistical Analysis 8                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Statistical analysis description:                                                                                                                                                    |                                                                                                   |
| P-value calculated according to the Cochran-Mantel-Haenszel test adjusted for baseline weight ( $\leq 100$ kg vs $> 100$ kg) and prior exposure to TNF antagonists (0 vs $\geq 1$ ). |                                                                                                   |
| Comparison groups                                                                                                                                                                    | Adalimumab/Rerandomized to Adalimumab (Part B) v Adalimumab/Rerandomized to Risankizumab (Part B) |
| Number of subjects included in analysis                                                                                                                                              | 109                                                                                               |
| Analysis specification                                                                                                                                                               | Pre-specified                                                                                     |
| Analysis type                                                                                                                                                                        | other                                                                                             |
| P-value                                                                                                                                                                              | $< 0.001$                                                                                         |
| Method                                                                                                                                                                               | Cochran-Mantel-Haenszel                                                                           |
| Parameter estimate                                                                                                                                                                   | Difference in percentage of participants                                                          |
| Point estimate                                                                                                                                                                       | 38.9                                                                                              |
| Confidence interval                                                                                                                                                                  |                                                                                                   |
| level                                                                                                                                                                                | 95 %                                                                                              |
| sides                                                                                                                                                                                | 2-sided                                                                                           |
| lower limit                                                                                                                                                                          | 22                                                                                                |
| upper limit                                                                                                                                                                          | 55.8                                                                                              |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug, up to 48 weeks

Adverse event reporting additional description:

AEs in Part A defined as events from the first dose of drug in Part A until prior to the first dose in Part B (Week16) or up to 15 weeks after the last dose of study drug if the participant discontinued in Part A;

AEs in Part B defined as events from first dose of drug in Part B (Week16) until up to 15 weeks after last dose of study drug.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 20.0 |
|--------------------|------|

### Reporting groups

|                       |                     |
|-----------------------|---------------------|
| Reporting group title | Adalimumab (Part A) |
|-----------------------|---------------------|

Reporting group description:

Participants randomized to receive double-blind adalimumab 80 mg at Week 0, then 40 milligram (mg) at Week 1 and every 2 weeks for 15 weeks (Part A).

|                       |                       |
|-----------------------|-----------------------|
| Reporting group title | Risankizumab (Part A) |
|-----------------------|-----------------------|

Reporting group description:

Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A) continued to receive risankizumab at Weeks 16 and 28.

|                       |                                                |
|-----------------------|------------------------------------------------|
| Reporting group title | Adalimumab/Rerandomized to Adalimumab (Part B) |
|-----------------------|------------------------------------------------|

Reporting group description:

Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to continue to receive adalimumab 40 mg every 2 weeks through Week 41 (Part B).

|                       |                                                  |
|-----------------------|--------------------------------------------------|
| Reporting group title | Adalimumab/Rerandomized to Risankizumab (Part B) |
|-----------------------|--------------------------------------------------|

Reporting group description:

Participants who were inadequate responders after receiving adalimumab in Part A, and re-randomized to receive risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).

|                       |                                  |
|-----------------------|----------------------------------|
| Reporting group title | Adalimumab/Risankizumab (Part B) |
|-----------------------|----------------------------------|

Reporting group description:

Participants who were nonresponders after receiving adalimumab in Part A switched to risankizumab 150 mg at Weeks 16, 20, and 32 (Part B).

|                       |                                    |
|-----------------------|------------------------------------|
| Reporting group title | Risankizumab/Risankizumab (Part B) |
|-----------------------|------------------------------------|

Reporting group description:

Participants randomized to receive double-blind risankizumab in Part A continued to receive risankizumab 150 mg at Weeks 16, and 28 (Part B).

| Serious adverse events                            | Adalimumab (Part A) | Risankizumab (Part A) | Adalimumab/Rerandomized to Adalimumab (Part B) |
|---------------------------------------------------|---------------------|-----------------------|------------------------------------------------|
| Total subjects affected by serious adverse events |                     |                       |                                                |
| subjects affected / exposed                       | 9 / 304 (2.96%)     | 10 / 301 (3.32%)      | 2 / 56 (3.57%)                                 |
| number of deaths (all causes)                     | 2                   | 1                     | 2                                              |
| number of deaths resulting from adverse events    | 1                   | 0                     | 0                                              |

|                                                                     |                 |                 |                |
|---------------------------------------------------------------------|-----------------|-----------------|----------------|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                 |                 |                |
| Basal cell carcinoma                                                |                 |                 |                |
| subjects affected / exposed                                         | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0          |
| Gallbladder cancer                                                  |                 |                 |                |
| subjects affected / exposed                                         | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 1 / 1           | 0 / 0           | 0 / 0          |
| Invasive lobular breast carcinoma                                   |                 |                 |                |
| subjects affected / exposed                                         | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0          |
| Prostate cancer                                                     |                 |                 |                |
| subjects affected / exposed                                         | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0          |
| Vascular disorders                                                  |                 |                 |                |
| Hypertensive crisis                                                 |                 |                 |                |
| subjects affected / exposed                                         | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0          |
| Surgical and medical procedures                                     |                 |                 |                |
| Abortion induced                                                    |                 |                 |                |
| subjects affected / exposed                                         | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0          |
| Reproductive system and breast disorders                            |                 |                 |                |
| Haemorrhagic ovarian cyst                                           |                 |                 |                |
| subjects affected / exposed                                         | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all                     | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all                          | 0 / 0           | 0 / 0           | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders                     |                 |                 |                |

|                                                |                                                 |                 |                 |                |
|------------------------------------------------|-------------------------------------------------|-----------------|-----------------|----------------|
| Asthma                                         | subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Respiratory failure                            | subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Psychiatric disorders                          |                                                 |                 |                 |                |
| Alcohol withdrawal syndrome                    | subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Anxiety                                        | subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Depression                                     | subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Suicide attempt                                | subjects affected / exposed                     | 1 / 304 (0.33%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 1           | 0 / 1           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Investigations                                 |                                                 |                 |                 |                |
| Anticoagulation drug level above therapeutic   | subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
|                                                | occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
|                                                | deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Injury, poisoning and procedural complications |                                                 |                 |                 |                |
| Fall                                           |                                                 |                 |                 |                |

|                                                 |                 |                 |                |
|-------------------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Joint dislocation                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Radius fracture                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Respiratory fume inhalation disorder            |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Upper limb fracture                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Congenital, familial and genetic disorders      |                 |                 |                |
| Macrocornea                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cardiac disorders                               |                 |                 |                |
| Acute myocardial infarction                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0          |
| Cardiac failure congestive                      |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

|                                                 |                 |                 |                |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Coronary artery occlusion                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Myocardial infarction                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Palpitations                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Nervous system disorders                        |                 |                 |                |
| Syncope                                         |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Blood and lymphatic system disorders            |                 |                 |                |
| Lymphadenopathy mediastinal                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Eye disorders                                   |                 |                 |                |
| Macular hole                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastrointestinal disorders                      |                 |                 |                |
| Abdominal pain                                  |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastric perforation                             |                 |                 |                |

|                                                 |                 |                 |                |
|-------------------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastritis                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pancreatitis                                    |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hepatobiliary disorders                         |                 |                 |                |
| Cholelithiasis                                  |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Liver injury                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                 |                 |                |
| Back pain                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Musculoskeletal chest pain                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                 |                 |                |
| Abdominal abscess                               |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0          |

|                                                 |                 |                 |                |
|-------------------------------------------------|-----------------|-----------------|----------------|
| Erysipelas                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Influenza                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Perirectal abscess                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 1 / 301 (0.33%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Sepsis                                          |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0          |
| Urinary tract infection                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Metabolism and nutrition disorders              |                 |                 |                |
| Diabetes mellitus                               |                 |                 |                |
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Diabetes mellitus inadequate control            |                 |                 |                |
| subjects affected / exposed                     | 0 / 304 (0.00%) | 0 / 301 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Diabetic ketoacidosis                           |                 |                 |                |



|                                                 |                 |                 |                |
|-------------------------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 1 / 304 (0.33%) | 0 / 301 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

| <b>Serious adverse events</b>                                       | Adalimumab/Rerandomized to Risankizumab (Part B) | Adalimumab/Risankizumab (Part B) | Risankizumab/Risankizumab (Part B) |
|---------------------------------------------------------------------|--------------------------------------------------|----------------------------------|------------------------------------|
| Total subjects affected by serious adverse events                   |                                                  |                                  |                                    |
| subjects affected / exposed                                         | 3 / 53 (5.66%)                                   | 4 / 38 (10.53%)                  | 12 / 294 (4.08%)                   |
| number of deaths (all causes)                                       | 0                                                | 0                                | 0                                  |
| number of deaths resulting from adverse events                      | 0                                                | 0                                | 0                                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                                  |                                  |                                    |
| Basal cell carcinoma                                                |                                                  |                                  |                                    |
| subjects affected / exposed                                         | 0 / 53 (0.00%)                                   | 0 / 38 (0.00%)                   | 1 / 294 (0.34%)                    |
| occurrences causally related to treatment / all                     | 0 / 0                                            | 0 / 0                            | 1 / 1                              |
| deaths causally related to treatment / all                          | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| Gallbladder cancer                                                  |                                                  |                                  |                                    |
| subjects affected / exposed                                         | 0 / 53 (0.00%)                                   | 0 / 38 (0.00%)                   | 0 / 294 (0.00%)                    |
| occurrences causally related to treatment / all                     | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| deaths causally related to treatment / all                          | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| Invasive lobular breast carcinoma                                   |                                                  |                                  |                                    |
| subjects affected / exposed                                         | 0 / 53 (0.00%)                                   | 0 / 38 (0.00%)                   | 0 / 294 (0.00%)                    |
| occurrences causally related to treatment / all                     | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| deaths causally related to treatment / all                          | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| Prostate cancer                                                     |                                                  |                                  |                                    |
| subjects affected / exposed                                         | 0 / 53 (0.00%)                                   | 0 / 38 (0.00%)                   | 1 / 294 (0.34%)                    |
| occurrences causally related to treatment / all                     | 0 / 0                                            | 0 / 0                            | 0 / 1                              |
| deaths causally related to treatment / all                          | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| Vascular disorders                                                  |                                                  |                                  |                                    |
| Hypertensive crisis                                                 |                                                  |                                  |                                    |
| subjects affected / exposed                                         | 0 / 53 (0.00%)                                   | 0 / 38 (0.00%)                   | 0 / 294 (0.00%)                    |
| occurrences causally related to treatment / all                     | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| deaths causally related to treatment / all                          | 0 / 0                                            | 0 / 0                            | 0 / 0                              |
| Surgical and medical procedures                                     |                                                  |                                  |                                    |
| Abortion induced                                                    |                                                  |                                  |                                    |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Reproductive system and breast disorders        |                |                |                 |
| Haemorrhagic ovarian cyst                       |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                |                |                 |
| Asthma                                          |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Respiratory failure                             |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Psychiatric disorders                           |                |                |                 |
| Alcohol withdrawal syndrome                     |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 38 (2.63%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Anxiety                                         |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Depression                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Suicide attempt                                 |                |                |                 |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Investigations                                  |                |                |                 |
| Anticoagulation drug level above therapeutic    |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 38 (2.63%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Injury, poisoning and procedural complications  |                |                |                 |
| Fall                                            |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Joint dislocation                               |                |                |                 |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Radius fracture                                 |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Respiratory fume inhalation disorder            |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Upper limb fracture                             |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Congenital, familial and genetic disorders      |                |                |                 |
| Macrocornea                                     |                |                |                 |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Cardiac disorders</b>                        |                |                |                 |
| Acute myocardial infarction                     |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Cardiac failure congestive                      |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Coronary artery occlusion                       |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 38 (2.63%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Myocardial infarction                           |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Palpitations                                    |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Nervous system disorders</b>                 |                |                |                 |
| Syncope                                         |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Blood and lymphatic system disorders</b>     |                |                |                 |
| Lymphadenopathy mediastinal                     |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| Eye disorders                                   |                |                |                 |
| Macular hole                                    |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Gastrointestinal disorders                      |                |                |                 |
| Abdominal pain                                  |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 38 (2.63%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Gastric perforation                             |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Gastritis                                       |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Pancreatitis                                    |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Hepatobiliary disorders                         |                |                |                 |
| Cholelithiasis                                  |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Liver injury                                    |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                |                |                 |
| Back pain                                       |                |                |                 |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Musculoskeletal chest pain                      |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Infections and infestations                     |                |                |                 |
| Abdominal abscess                               |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Erysipelas                                      |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 2 / 38 (5.26%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 2          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Influenza                                       |                |                |                 |
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Perirectal abscess                              |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Pneumonia                                       |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 38 (2.63%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Sepsis                                          |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 1 / 38 (2.63%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Urinary tract infection                         |                |                |                 |

|                                                 |                |                |                 |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed                     | 1 / 53 (1.89%) | 0 / 38 (0.00%) | 1 / 294 (0.34%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| <b>Metabolism and nutrition disorders</b>       |                |                |                 |
| Diabetes mellitus                               |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Diabetes mellitus inadequate control            |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |
| Diabetic ketoacidosis                           |                |                |                 |
| subjects affected / exposed                     | 0 / 53 (0.00%) | 0 / 38 (0.00%) | 0 / 294 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0           |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                                   | Adalimumab (Part A) | Risankizumab (Part A) | Adalimumab/Rerandomized to Adalimumab (Part B) |
|---------------------------------------------------------------------|---------------------|-----------------------|------------------------------------------------|
| Total subjects affected by non-serious adverse events               |                     |                       |                                                |
| subjects affected / exposed                                         | 71 / 304 (23.36%)   | 76 / 301 (25.25%)     | 21 / 56 (37.50%)                               |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                     |                       |                                                |
| Seborrhoeic keratosis                                               |                     |                       |                                                |
| subjects affected / exposed                                         | 0 / 304 (0.00%)     | 0 / 301 (0.00%)       | 0 / 56 (0.00%)                                 |
| occurrences (all)                                                   | 0                   | 0                     | 0                                              |
| Vascular disorders                                                  |                     |                       |                                                |
| Hypertension                                                        |                     |                       |                                                |
| subjects affected / exposed                                         | 8 / 304 (2.63%)     | 1 / 301 (0.33%)       | 1 / 56 (1.79%)                                 |
| occurrences (all)                                                   | 12                  | 1                     | 1                                              |
| Nervous system disorders                                            |                     |                       |                                                |
| Headache                                                            |                     |                       |                                                |
| subjects affected / exposed                                         | 20 / 304 (6.58%)    | 12 / 301 (3.99%)      | 3 / 56 (5.36%)                                 |
| occurrences (all)                                                   | 29                  | 13                    | 4                                              |

|                                                                                                                                                                                                                                                                                               |                                                                                  |                                                                                  |                                                                            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Respiratory, thoracic and mediastinal disorders<br>Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                     | 3 / 304 (0.99%)<br>3                                                             | 6 / 301 (1.99%)<br>6                                                             | 1 / 56 (1.79%)<br>1                                                        |
| Musculoskeletal and connective tissue disorders<br>Arthralgia<br>subjects affected / exposed<br>occurrences (all)<br><br>Back pain<br>subjects affected / exposed<br>occurrences (all)                                                                                                        | 9 / 304 (2.96%)<br>12<br><br>6 / 304 (1.97%)<br>6                                | 11 / 301 (3.65%)<br>12<br><br>9 / 301 (2.99%)<br>9                               | 3 / 56 (5.36%)<br>5<br><br>3 / 56 (5.36%)<br>3                             |
| Infections and infestations<br>Bronchitis<br>subjects affected / exposed<br>occurrences (all)<br><br>Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all)<br><br>Viral upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 3 / 304 (0.99%)<br>3<br><br>12 / 304 (3.95%)<br>15<br><br>24 / 304 (7.89%)<br>29 | 4 / 301 (1.33%)<br>4<br><br>21 / 301 (6.98%)<br>26<br><br>26 / 301 (8.64%)<br>31 | 3 / 56 (5.36%)<br>3<br><br>5 / 56 (8.93%)<br>5<br><br>7 / 56 (12.50%)<br>8 |

| <b>Non-serious adverse events</b>                                                                                                                | Adalimumab/Rerandomized to Risankizumab (Part B) | Adalimumab/Risankizumab (Part B) | Risankizumab/Risankizumab (Part B) |
|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|----------------------------------|------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                                                             | 24 / 53 (45.28%)                                 | 16 / 38 (42.11%)                 | 95 / 294 (32.31%)                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)<br>Seborrhoeic keratosis<br>subjects affected / exposed<br>occurrences (all) | 0 / 53 (0.00%)<br>0                              | 2 / 38 (5.26%)<br>2              | 2 / 294 (0.68%)<br>2               |
| Vascular disorders<br>Hypertension<br>subjects affected / exposed<br>occurrences (all)                                                           | 1 / 53 (1.89%)<br>1                              | 3 / 38 (7.89%)<br>3              | 9 / 294 (3.06%)<br>9               |
| Nervous system disorders                                                                                                                         |                                                  |                                  |                                    |



|                                                                                                                                                                                                                                                                                               |                                                                              |                                                                             |                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Headache<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                                                                                  | 3 / 53 (5.66%)<br>3                                                          | 2 / 38 (5.26%)<br>2                                                         | 6 / 294 (2.04%)<br>7                                                               |
| Respiratory, thoracic and mediastinal disorders<br>Oropharyngeal pain<br>subjects affected / exposed<br>occurrences (all)                                                                                                                                                                     | 2 / 53 (3.77%)<br>2                                                          | 2 / 38 (5.26%)<br>2                                                         | 3 / 294 (1.02%)<br>4                                                               |
| Musculoskeletal and connective tissue disorders<br>Arthralgia<br>subjects affected / exposed<br>occurrences (all)<br><br>Back pain<br>subjects affected / exposed<br>occurrences (all)                                                                                                        | 2 / 53 (3.77%)<br>2<br><br>2 / 53 (3.77%)<br>3                               | 0 / 38 (0.00%)<br>0<br><br>0 / 38 (0.00%)<br>0                              | 4 / 294 (1.36%)<br>4<br><br>6 / 294 (2.04%)<br>6                                   |
| Infections and infestations<br>Bronchitis<br>subjects affected / exposed<br>occurrences (all)<br><br>Upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all)<br><br>Viral upper respiratory tract infection<br>subjects affected / exposed<br>occurrences (all) | 2 / 53 (3.77%)<br>2<br><br>4 / 53 (7.55%)<br>6<br><br>14 / 53 (26.42%)<br>19 | 2 / 38 (5.26%)<br>2<br><br>3 / 38 (7.89%)<br>5<br><br>9 / 38 (23.68%)<br>14 | 7 / 294 (2.38%)<br>8<br><br>34 / 294 (11.56%)<br>44<br><br>39 / 294 (13.27%)<br>48 |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date            | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17 June 2016    | Abbreviation added. "Biologic therapy history" changed to "Psoriasis therapy history" and % body surface area involvement at Visit 1 and 2 added. Anti-drug antibodies sampling at Week 4 added. Randomization, Re-Randomization at Visit 8 should read footer 14. Several text changed in Overall Trial Design and Plan. Clarification on how efficacy data will be used upon submission to the Data Monitoring Committee (DMC) as well as additional information on unbinding. Thrombotic events added. New inclusion criterion added. Exclusion criteria number 4 and 7 slightly changed. Patients that discontinue study medication should complete all study visits and procedures as initially planned, if possible. Method of assigning patients to treatment groups Section revised. Revised text to specify timing of vital sign measurements and hypersensitivity monitoring at dosing visits; further information regarding drug injection details; additional description on patients late visit added. Added facitinib (Xeljanz®) and apremilast (Otezla®) and removed efalizumab (Raptiva®). Added "Absolute Psoriasis Area Severity Index (PASI) score of <3 at all visits collected" in further endpoints. Some laboratory parameters are better specified. Added Albumin/creatinine ratio in urine. Removed information from details of trial procedures. Some information added and removed from baseline conditions. Last paragraph of treatment period section revised. Patients that discontinue study medication should complete all study visits and procedures as initially planned, if possible. Clarified the important protocol violations. Hypothesis tests as described in Section 7.2 will be repeated on the Per Protocol Set or Re-Randomized Per Protocol Set, as appropriate. Added "Time to onset of Endpoint" definition. Clarified Residual Effect Period (REP). Interim analysis planning added. The Work Limitations Questionnaire (WLQ) is not applicable to unemployed patients added. |
| 05 July 2016    | Clarification provided in section 11, to implement only after approval of the Institutional Review Board (IRB) / Independent Ethics Committee (IEC) / Competent Authorities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 17 October 2016 | 1. In title page changed BI drug or BI 655066 to refer to either names for this compound: BI 655066/ABBV-066 (risankizumab). 2. Changed sponsor from Boehringer Ingelheim (BI) to AbbVie in the USA; BI remains the sponsor for all other participating countries. 3. Changed text to specify Statistical Evaluation will be done by AbbVie according to their SOPs.. 4. Updated text to "AbbVie/Boehringer Ingelheim reserves the right to discontinue the trial overall or at a particular trial site at any time for the following reasons". 5. Changed DNA banking sample storage from Boehringer Ingelheim to AbbVie or a third party delegate. 6. Skin biopsies will be collected only at Visit 2 (lesional and non-lesional) and at Visit 7 (only lesional) as shown in the Flow Chart. 7. Changed text to specify that AbbVie summary tables and listings will be produced and analyses are based on AbbVie standards.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported